JMP Securities Downgrades Ambrx Biopharma to Market Perform
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has downgraded Ambrx Biopharma (NASDAQ:AMAM) from Market Outperform to Market Perform, indicating a change in the firm's outlook on the stock.

January 10, 2024 | 10:23 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ambrx Biopharma was downgraded by JMP Securities from Market Outperform to Market Perform, which may influence investors' perception and could potentially impact the stock's performance in the short term.
Downgrades by analysts can lead to a negative perception among investors and often result in a short-term decline in the stock price. Given that the downgrade is from a higher rating of Market Outperform to Market Perform, it suggests a less bullish outlook on the stock, which could lead to selling pressure.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100